Reversible Silencing of Neuronal Excitability in Behaving Mice by a Genetically Targeted, Ivermectin-Gated Cl- Channel

Neuron

Volumn 54, Issue 1, 2007, Pages 35-49

  Lerchner, Walter ^a   Xiao, Cheng ^a   Nashmi, Raad ^a   Slimko, Eric M ^a   van Trigt, Laurent ^a   Lester, Henry A ^a   Anderson, David J ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

MOLNEURO

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHLORIDE CHANNEL; GLUTAMATE RECEPTOR 1; GLUTAMIC ACID; IVERMECTIN;

ACTION POTENTIAL; ALPHA CHAIN; ARTICLE; BEHAVIOR; BETA CHAIN; CAENORHABDITIS ELEGANS; CELL SPECIFICITY; CHANNEL GATING; CIRCLING BEHAVIOR; CORPUS STRIATUM; DOSE RESPONSE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC PROCEDURES; GENETIC REGULATION; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RESPONSE TIME; SINGLE DRUG DOSE; TRANSGENIC ANIMAL; WAKEFULNESS;

ACTION POTENTIALS; AMPHETAMINE; ANIMALS; ANTIPARASITIC AGENTS; BEHAVIOR, ANIMAL; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CHLORIDE CHANNELS; CORPUS STRIATUM; DRUG INTERACTIONS; GENE EXPRESSION; ION CHANNEL GATING; IVERMECTIN; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; NEURAL INHIBITION; NEURONS; PHOSPHOPYRUVATE HYDRATASE; TIME FACTORS;

EID: 33947693328     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2007.02.030     Document Type: Article

References (42)

1. Anden N.E., Hfuxe K., Hamberger B., and Hokfelt T. A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiol. Scand. 67 (1966) 306-312
2. Berke J.D., Okatan M., Skurski J., and Eichenbaum H.B. Oscillatory entrainment of striatal neurons in freely moving rats. Neuron 43 (2004) 883-896
3. Burdett E.C., Heckmann R.A., and Ochoa R. Evaluation of five treatment regimens and five diagnostic methods for murine mites (Myocoptes musculinus and Myobia musculi). Contemp. Top. Lab. Anim. Sci. 36 (1997) 73-76
4. Callaway E.M. A molecular and genetic arsenal for systems neuroscience. Trends Neurosci. 28 (2005) 196-201
5. Chabala J.C., Mrozik H., Tolman R.L., Eskola P., Lusi A., Peterson L.H., Woods M.F., Fisher M.H., Campbell W.C., Egerton J.R., and Ostlind D.A. Ivermectin, a new broad-spectrum antiparasitic agent. J. Med. Chem. 23 (1980) 1134-1136
6. Conole J., Wilkinson M.J., and McKellar Q.A. Some observations on the pharmacological properties of ivermectin during treatment of a mite infestation in mice. Contemp. Top. Lab. Anim. Sci. 42 (2003) 42-45
7. Davis J.A., Paylor R., McDonald M.P., Libbey M., Ligler A., Bryant K., and Crawley J.N. Behavioral effects of ivermectin in mice. Lab. Anim. Sci. 49 (1999) 288-296
8. Dawson G.R., Wafford K.A., Smith A., Marshall G.R., Bayley P.J., Schaeffer J.M., Meinke P.T., and McKernan R.M. Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. 295 (2000) 1051-1060
9. Deisseroth K., Feng G., Majewska A.K., Miesenbock G., Ting A., and Schnitzer M.J. Next-generation optical technologies for illuminating genetically targeted brain circuits. J. Neurosci. 26 (2006) 10380-10386
10. Geary T.G. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 21 (2005) 530-532
11. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., and Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 (2003) 917-925
12. Gosgnach S., Lanuza G.M., Butt S.J., Saueressig H., Zhang Y., Velasquez T., Riethmacher D., Callaway E.M., Kiehn O., and Goulding M. V1 spinal neurons regulate the speed of vertebrate locomotor outputs. Nature 440 (2006) 215-219
13. Graybiel A.M. The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol. 15 (2005) 638-644
14. Heintz N. Gene expression nervous system atlas (GENSAT). Nat. Neurosci. 7 (2004) 483
15. Ibanez-Tallon I., Wen H., Miwa J.M., Xing J., Tekinay A.B., Ono F., Brehm P., and Heintz N. Tethering naturally occurring peptide toxins for cell-autonomous modulation of ion channels and receptors in vivo. Neuron 43 (2004) 305-311
16. Jiang Z.G., and North R.A. Membrane properties and synaptic responses of rat striatal neurones in vitro. J. Physiol. 443 (1991) 533-553
17. Johns D.C., Marx R., Mains R.E., O'Rourke B., and Marban E. Inducible genetic suppression of neuronal excitability. J. Neurosci. 19 (1999) 1691-1697
18. Karpova A.Y., Tervo D.G., Gray N.W., and Svoboda K. Rapid and reversible chemical inactivation of synaptic transmission in genetically targeted neurons. Neuron 48 (2005) 727-735
19. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
20. Lechner H.A., Lein E.S., and Callaway E.M. A genetic method for selective and quickly reversible silencing of Mammalian neurons. J. Neurosci. 22 (2002) 5287-5290
21. Lein E.S., Hawrylycz M.J., Ao N., Ayres M., Bensinger A., Bernard A., Boe A.F., Boguski M.S., Brockway K.S., Byrnes E.J., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 (2007) 168-176 10.1038/nature05453 Published online December 6, 2006
22. Li P., Slimko E.M., and Lester H.A. Selective elimination of glutamate activation and introduction of fluorescent proteins into a Caenorhabditis elegans chloride channel. FEBS Lett. 528 (2002) 77-82
23. Nadeau H., McKinney S., Anderson D.J., and Lester H.A. ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. J. Neurophysiol. 84 (2000) 1062-1075
24. Nitabach M.N., Blau J., and Holmes T.C. Electrical silencing of Drosophila pacemaker neurons stops the free-running circadian clock. Cell 109 (2002) 485-495
25. Oberlander C., and Boissier J.R. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation. J. Pharmacol. 14 (1983) 401-404
26. Olds M.E., Jacques D.B., and Kopyov O. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra subregions. Synapse 59 (2006) 532-544
27. Roder J.D., and Stair E.L. An overview of ivermectin toxicosis. Vet. Hum. Toxicol. 40 (1998) 369-370
28. Schafer W.R. Deciphering the neural and molecular mechanisms of C. elegans behavior. Curr. Biol. 15 (2005) R723-R729
29. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
30. Schwarcz R., Fuxe K., Agnati L.F., Hokfelt T., and Coyle J.T. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors. Brain Res. 170 (1979) 485-495
31. Slimko E.M., and Lester H.A. Codon optimization of Caenorhabditis elegans GluCl ion channel genes for mammalian cells dramatically improves expression levels. J. Neurosci. Methods 124 (2003) 75-81
32. Slimko E.M., McKinney S., Anderson D.J., Davidson N., and Lester H.A. Selective electrical silencing of mammalian neurons in vitro by the use of invertebrate ligand-gated chloride channels. J. Neurosci. 22 (2002) 7373-7379
33. Tan E.M., Yamaguchi Y., Horwitz G.D., Gosgnach S., Lein E.S., Goulding M., Albright T.D., and Callaway E.M. Selective and quickly reversible inactivation of mammalian neurons in vivo using the Drosophila allatostatin receptor. Neuron 51 (2006) 157-170
34. Thum A.S., Knapek S., Rister J., Dierichs-Schmitt E., Heisenberg M., and Tanimoto H. Differential potencies of effector genes in adult Drosophila. J. Comp. Neurol. 498 (2006) 194-203
35. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367 (1971) 69-93
36. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
37. Willis G.L., and Kennedy G.A. The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease. Rev. Neurosci. 15 (2004) 75-87
38. Wilson C. Basal Ganglia. In: Shepherd G.M. (Ed). The Synaptic Organization of the Brain. Fourth Edition (1998), Oxford University Press, New York 329-375
39. Yamamoto M., Wada N., Kitabatake Y., Watanabe D., Anzai M., Yokoyama M., Teranishi Y., and Nakanishi S. Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain. J. Neurosci. 23 (2003) 6759-6767
40. Ye J.H., Zhang J., Xiao C., and Kong J.Q. Patch-clamp studies in the CNS illustrate a simple new method for obtaining viable neurons in rat brain slices: glycerol replacement of NaCl protects CNS neurons. J. Neurosci. Methods 158 (2006) 251-259
41. Yu C.R., Power J., Barnea G., O'Donnell S., Brown H.E., Osborne J., Axel R., and Gogos J.A. Spontaneous neural activity is required for the establishment and maintenance of the olfactory sensory map. Neuron 42 (2004) 553-566
42. Zhang X., Baader S.L., Bian F., Muller W., and Oberdick J. High level Purkinje cell specific expression of green fluorescent protein in transgenic mice. Histochem. Cell Biol. 115 (2001) 455-464